Superworth

ClearPoint Neuro CLPT

Medical - Instruments & Supplies, Healthcare
$9.95
−6.75%
Market cap
$318.9M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
7.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$45.5M
+33% on a year ago
Net margin
−79.4%
Free cash flow yield
−10.4%

ClearPoint Neuro trades at 7.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $45.5M over the last twelve months, up 33% on a year earlier with a −79% net margin.

Charts

Financials

Income statement for CLPT, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$6.8M+32%$7.6M+41%$7.9M+32%$8.1M+41%$7.8M+14%$8.5M+11%$9.2M+17%$8.9M+9%$10.4M+34%$12.1M+43%$10.9M+18%$12.1M+36%
Cost of revenue$2.8M+55%$3.1M+40%$2.9M+2%$3.3M+32%$3M+8%$3.4M+8%$3.7M+28%$3.3M−0%$4M+33%$4.4M+30%$4.2M+14%$5M+54%
Gross profit$4M+19%$4.5M+41%$5M+60%$4.8M+48%$4.8M+19%$5.1M+13%$5.6M+11%$5.6M+16%$6.4M+35%$7.8M+51%$6.7M+21%$7.1M+26%
R&D$2.7M−9%$2.6M−13%$3.1M−14%$3.3M+37%$3.3M+26%$3.4M+29%$3.8M+23%$3.5M+4%$3.2M−3%$4.5M+34%$4.6M+21%$4M+16%
SG&A$2.7M+15%$2.8M−5%$2.8M−13%$3.1M+8%$3.3M+20%$4.1M+44%$3.4M+23%$3.6M+14%$5.4M+67%$5M+22%$5.6M+64%$3.8M+7%
−$4.7M+5%−$4.2M−26%−$4.7M−34%−$5.2M+5%−$5.6M+20%−$6.2M+46%−$5.7M+20%−$5.3M+2%−$7M+25%−$8.5M+38%−$10.2M+80%−$6.3M+20%
Interest expensen/an/an/an/an/a$0$365K$939K$1.1M$1.4M$1.4M+287%$1.4M+54%
Pre-tax incomen/a−$4.1M−$4.4M−$5M−$5.4M−$6M+45%−$5.8M+32%−$5.9M+19%−$7.8M+44%−$9.5M+59%−$11.4M+96%−$7.5M+27%
n/a$15K$15K$14K−$32K$18K+20%$25K+67%$8K−43%$4K$8K−56%−$38K−$4K
Net income−$4.6M+5%−$4.1M−26%−$4.4M−38%−$5M+3%−$5.4M+17%−$6M+45%−$5.8M+32%−$5.9M+18%−$7.8M+45%−$9.6M+59%−$11.3M+94%−$7.5M+27%
−$0.19+6%−$0.16−30%−$0.16−45%−$0.18−10%−$0.20+5%−$0.22+38%−$0.21+31%−$0.21+17%−$0.27+35%−$0.32+46%−$0.38+81%−$0.24+14%
24.6M+0%25.5M+4%27.5M+12%27.6M+12%27.6M+12%27.7M+9%28.3M+3%28.4M+3%28.8M+5%29.5M+7%30.2M+7%31M+9%

Gross profit: 38 periods, Q1 FY11 to Q1 FY21: not printed by the filing, worked out from its own lines.

EPS, diluted: 15 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 15 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest ClearPoint Neuro's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CLPTClearPoint Neuro$318.9Mn/mn/a7.0×+33%−79.4%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
TCMDTactile Systems Technology$518.1M21.2×62.3×1.5×+17%7.1%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
Peer median$434.4M19.4×24.0×1.7×+5%7.8%

More on ClearPoint Neuro

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .